Celleo Biotech
David Kneen has a diverse work experience in the biotech and healthcare industry. David co-founded and currently serves as the Chief Executive Officer and Head of Commercial at Celleo Biotech, where they focus on intelligent production systems for Cell & Gene Therapies. Prior to that, they worked at Neo-Bionica in Corporate Development, structuring collaboration deals for neurotech companies. David also served as the Industry Interface Representative at CCRM Australia, and as the Principal at Kneen Advisory. Additionally, David has held positions at CH4Global, Invetech, Fortive, CRC for Cell Therapy Manufacturing, and Deakin University, where they contributed to various roles ranging from COO to Program Manager and Advisory Board Member.
David Kneen attended Melbourne Business School from 2008 to 2010 and earned their MBA with a focus on Finance, Business Strategy, and Innovation Management. In 2009, they also attended HEC Paris for a short period to further their MBA studies. Prior to that, from 1997 to 2002, David Kneen studied at the University of Melbourne, completing a BE/BSc degree in Mechanical Engineering, Applied Mathematics, and Physics. Their educational journey began at Trinity Grammar School, Kew, where they attended from 1991 to 1996. No specific degree or field of study is provided for this period.
This person is not in any teams
This person is not in any offices
Celleo Biotech
Celleo originated at the intersection of great biology and great engineering. Sparks fly at the intersection. Our mission is to enable Cell & Gene Therapies to deliver population-level health outcomes, realizing the extraordinary potential of humanity’s most powerful therapeutic modality – our cells, augmented. We contribute intelligent production systems for the manufacture of Cell & Gene Therapies. Our 3 co-founders each bring nearly 20 years of deep industry experience in the development and production of Cell & Gene Therapies. Celleo develops GMP production systems in collaboration with leading commercial biotherapeutics players, developers of novel therapeutics at pre-clinical to clinical stage, CDMOs, and major university medical centers. Our production systems seek to accommodate, not dictate, the diversity of processes, modalities and business models characteristic of our vibrant industry. Steve Jobs predicted “…the biggest innovations of the 21st century will be at the intersection of biology and technology.” Today’s Cell & Gene Therapy industry is approaching a tipping point – from a limited set of therapeutics changing the lives of a fortunate few, to a broadly available toolkit for physicians providing a new standard of personalized care. We’re here to hasten that transition. Millions of patients in need deserve it. Thousands of Cell Therapy professionals deserve it too.